We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

111 hedge funds and large institutions have $216M invested in Endocyte, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 111 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $822K

Holders
111
Holders Change
+111
Holders Change %
–
% of All Funds
3.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
111
Increased
–
Reduced
–
Closed
–
Calls
$1.55M
Puts
$822K
Net Calls
+$732K
Net Calls Change
+$732K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BB
1
BB Biotech
Switzerland
$30.7M +$31.5M +2,339,345 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$25.6M +$26.2M +1,946,041 New
BFA
3
BlackRock Fund Advisors
California
$14.4M +$14.8M +1,094,257 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.5M +$11.8M +874,279 New
AWMDMG
5
Austin W. Marxe & David M. Greenhouse
New York
$11.2M +$11.5M +850,000 New
O
6
OrbiMed
New York
$8.69M +$8.93M +662,000 New
State Street
7
State Street
Massachusetts
$6.71M +$6.89M +511,203 New
PA
8
Pinnacle Associates
New York
$6.15M +$6.32M +468,680 New
TCM
9
Tang Capital Management
California
$6.12M +$6.28M +465,763 New
Northern Trust
10
Northern Trust
Illinois
$5.49M +$5.64M +418,373 New
BIT
11
BlackRock Institutional Trust
California
$5.44M +$5.58M +414,181 New
MG
12
Meditor Group
Bermuda
$4.4M +$4.52M +335,000 New
NI
13
Numeric Investors
Massachusetts
$4.19M +$4.3M +319,110 New
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$3.95M +$4.06M +300,800 New
AQR Capital Management
15
AQR Capital Management
Connecticut
$3.83M +$3.93M +291,580 New
Deutsche Bank
16
Deutsche Bank
Germany
$3.01M +$3.1M +229,613 New
CRC
17
Curi RMB Capital
Illinois
$2.9M +$2.98M +221,000 New
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$2.73M +$2.81M +208,100 New
TCIM
19
TIAA CREF Investment Management
New York
$2.48M +$2.55M +189,196 New
QBFM
20
QS Batterymarch Financial Management
New York
$2.42M +$2.49M +184,300 New
American Century Companies
21
American Century Companies
Missouri
$2.38M +$2.44M +180,983 New
BIM
22
Bogle Investment Management
Massachusetts
$2.04M +$2.09M +155,320 New
FCM
23
Farallon Capital Management
California
$2.04M +$2.09M +155,000 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.98M +$2.04M +150,949 New
DCM
25
Driehaus Capital Management
Illinois
$1.87M +$1.92M +142,103 New
1
2 3 4 5

ECYT Hedge Fund Activity: Q2 2013 in Review

111 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2013, worth a combined $216M.

Buyers outnumbered sellers: 111 funds opened new ECYT positions and 0 closed out — a net gain of 111 holders — while 0 added to existing stakes and 0 trimmed.

  • 111 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $216M of Endocyte, Inc. Common Stock stock for Q2 2013.
  • 111 funds opened new Endocyte, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +111 holders.

Based on aggregated 13F filings for Q2 2013.